DR-347 Comprehensive characterization of the immunogenomic landscape of metastatic tumors
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-347 Comprehensive characterization of the immunogenomic landscape of metastatic tumors
Escape from immune surveillance is one of the hallmarks of tumorigenesis. In this study, we aim to perform an extensive …
DR-360 Xenobiotic metabolizers in bladder cancer progression
Metastasis marks the culmination of tumorigenesis and is the leading cause of mortality in cancer. The underlying molecular processes that …
DR-355 Mapping the germline genetic architecture of cancer using genome sequencing
Cancer is a leading cause of death worldwide, but many tumors are treatable if intercepted at an early stage. Thus, …
DR-335 Leveraging mutational processes to uncover cancer biomarkers
Cancers develop due to a range of genomic alterations, of which mutations are the most frequent. Sequencing cancer genomes reveals …
DR-346 Investigating Immune Evasion in Gastrointestinal Malignancies
Colon, rectal, stomach, and esophageal cancers are able to evade detection from our immune system, however the way these tumors …
DR-344 The role of T-cell associated chemokines in shaping the tumor immune interphase and for the initiation of effective anti-tumor immune responses in advanced skin cancers in the course of tumor progression
T cell based immunotherapies have significantly advanced the treatment of advanced skin cancers and malignant melanoma in particular. However, initial …
DR-310 Clinical actionability for and heritable factors involved in glioblastoma
This project aims to use whole genome sequencing data to 1) describe the driver landscape of glioblastoma, 2) determine potential …
DR-336 Genomic signatures of cancer therapies
Cancer is a disease characterized by genomic alterations, including mutations, copy number variations, and structural variants. These genomic alterations can …
DR-305 ctDNA analysis to monitor response to neoadjuvant chemoradiation in esohageal cancer patients
After neoadjuvant treatment of esophageal cancer, the standard treatment is resection. However, in circa 20% of patients, no vital tumor …
DR-279 Identification and validation of genomic and transcriptomic based biomarkers for organoid and patient response in a large colorectal cancer cohort
With this project, we aim to personalize cancer treatment and find new treatments for cancer sub-types by investigating the (expression …
DR-340 Discovering novel noncoding cancer drivers using genomic conformation and context models
Cancer cells are characterized by the accumulation of genetic mutations, only few of which are needed to trigger the malignancy. …
DR-325 Deciphering the role of Trem1 signaling in breast cancer metastasis
Trem1 is an LPS dimerizing receptor that is mainly involved in bacterial and danger-damage-associated signals. Yet, its role in cancer …
In ons vak is het heel belangrijk om naast de kennis over de patiënt meer kennis te hebben van de tumor van de patiënt.